Shots::stoohthShots:

• Bavarian signs an exclusive head of terms agreement with AdaptVac- (a joint venture of ExpreS2ion and NextGen Vaccines) to license AdaptVac’s capsid VLP-based SARS-CoV-2 subunit vaccine. A final agreement is expected to be consummated within the next two months
• Following the execution of the final license agreement- AdaptVac to receive upfront- development & commercial milestones along with royalties on sales. The agreement will have no impact on Bavarian’s financial guidance for 2020
• Bavarian will support the consortium called the PREVENT-nCoV to achieve clinical proof-of-concept and will be responsible for clinical development and global commercialization of vaccine with the anticipated initiation of clinical study in late 2020

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Wikipedia